The FDA approved forensicata. Uh, in a very broad, uh, with a very broad indication. The indication says only, uh, brensicative is indicated for patients with non-cystic fibrosis, bronchiectasis. There are no, uh, other requirements, no stipulations. It simply says patients with non-cystic fibrosis, bronchiectasis. Now, recall that the, uh, Major outcomes of the two large studies included uh diminished frequency of uh exacerbations and maintenance of pulmonary function. Now, neither of those is mentioned as a part of the FDA indication for the drug. Unfortunately, uh, those two, Uh, stipulations have been, uh, embraced by, uh, third-party carriers. So, uh, Getting the drug for patients and having it approved by insurance now frequently requires demonstration of at least 2 bronchiectasis exam exacerbations in the prior 12 months, or some compromise in pulmonary function or uh the uh demonstration of declining uh pulmonary function, even if it's still normal. So my approach is that I think this drug is so valuable, and I believe what the FDA meant when they gave it this broad indication that I tried to find a way to prescribe it for as many people as I can. Um, usually, it, it, in our population, it's not too hard to identify a 12-month period with two exacerbations or, uh, uh. Compromised in the pulmonary function testing. But the drug, uh, uh, has, is, is associated with considerable expense. So patients, uh, Cannot, uh, pay out of pocket for the drug practically. Um, but my, my feeling is that, uh, if I had bronchiectasis, knowing what I know about this drug, uh, I would want to take it.
Presenter
